What Ainnova Tech does

Ainnova Tech is a Nevada-registered health technology company, founded in 2020 and headquartered in San José, Costa Rica with a U.S. base in Houston, Texas and operations in Mexico City. The company has built VisionAI, a web-based AI platform that analyzes high-resolution retinal fundus images (captured via non-mydriatic cameras) to enable early detection of multiple diseases from a single non-invasive scan. Its clinically validated modules include diabetic retinopathy screening (>90% accuracy, in FDA pre-submission), a cardiovascular risk score (AICVD, validated by Apollo Hospitals on 2.3M+ data points), a prediabetes/type 2 diabetes risk model built on 40,000+ patient records using XGBoost (AUC 0.86), an AI liver fibrosis risk score (AUC 0.88), and a chronic kidney disease progression model (>85% accuracy). Active R&D targets age-related macular degeneration, glaucoma, and Alzheimer's detection, and the company holds a patented early-stage dementia detection technology.

The VisionAI platform is paired with proprietary Versatile Retinal Cameras and is commercialized through a multi-channel strategy: a joint venture with Avant Technologies (Ai-nova Acquisition Corp) for North America and Europe; an exclusive AI algorithm license and clinical collaboration with Apollo Hospitals for hospital-channel deployment across the Americas; direct distribution to opticians and eye care centers in Costa Rica, Mexico, Chile, and the Dominican Republic; and the recently acquired OTCHealth Inc., which brings agreements with major U.S. pharmacy chains. The revenue model is subscription / recurring platform licensing to medical facilities for preventive screening; pricing is quote-based and not publicly disclosed.

The company is small (1–10 employees) and pre-IPO, with stated intent to go public in 2025 and a pending full acquisition by Avant Technologies. Cumulative disclosed funding is approximately $5.8M across 2022–2025; no revenue is publicly disclosed. Commercial activity is currently concentrated in Latin American pilots, with FDA 510(k) clearance, ANVISA approval for Brazil, and U.S. retail pharmacy scaling through OTCHealth positioned as the principal near-term growth catalysts.

Name

Ainnova Tech

Legal name

Ainnova Tech Inc.

Website

https://ainnovatech.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Ainnova Tech is a Nevada-registered health tech company that builds VisionAI, an AI platform analyzing retinal images for early detection of diabetic retinopathy, cardiovascular risk, prediabetes, liver fibrosis, and chronic kidney disease. It serves opticians, clinics, hospitals, and pharmacies across the Americas through partnerships and licensing.

Ownership category

akta.pro rank

Product category

AI Medical Imaging Diagnostics

NAICS

Ophthalmic Goods Manufacturing (339115), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Ophthalmic Goods (3851)

akta.pro primary industry

Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB)

akta.pro secondary industries

Ocular Imaging & Diagnostic Testing Centers (HLAKAKAN), Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging) (HLAFAKAI), Retina & Vitreous Specialists (HLAKAKAE), Low Vision & Assistive Vision Devices (Magnifiers, Electronic Video Magnifiers, Wearable Vision Aids) (HLAHAJAN)

Keywords

• AI diagnostics
• Retinal imaging
• Diabetic retinopathy screening
• Preventive healthcare
• Medical imaging software

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. VisionAI Platform Licensing: AI-powered diagnostic platform for early disease detection licensed to healthcare providers, opticians, and eye care centers. Revenue generated through platform licensing to medical facilities using the technology for preventive screening.
2. Diagnostic Screening Services: AI-powered screening solutions delivered to primary care, pharmacies, and wellness centers. Non-invasive fundus eye tests and multi-disease risk assessments for preventive healthcare.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Core offering

Ainnova Tech develops and sells VisionAI, an AI-powered software platform that analyzes non-mydriatic retinal fundus images to detect diabetic retinopathy and other retinal diseases, delivering results in seconds with over 90% diagnostic accuracy. The platform extends beyond retinal screening with additional AI risk models for cardiovascular disease (AICVD), type 2 diabetes, liver fibrosis, and chronic kidney disease progression, validated against Apollo Hospitals' 2.3M+ data points. The company also develops proprietary Versatile Retinal Cameras and pursues FDA 510(k) clearance for U.S. commercialization while distributing through healthcare providers, opticians, eye care centers, hospital systems, and retail pharmacies.

Product overview

Ainnova Tech offers VisionAI, a unified AI-powered healthcare platform designed for early disease detection. The core platform centers on diabetic retinopathy screening through retinal fundus imaging, augmented by multiple AI-driven risk assessment modules including cardiovascular disease (AICVD Cardiac Risk Score), type 2 diabetes (Prediabetes AI Risk Assessment), liver fibrosis (AI Liver Fibrosis Risk Score), and chronic kidney disease (CKD Progression Risk Model). The company also develops proprietary Versatile Retinal Cameras. Active R&D efforts target Alzheimer's disease and additional eye conditions (AMD, glaucoma) detection. The company operates through partnerships including a joint venture with Avant Technologies (Ai-nova Acquisition Corp) for North America and Europe commercialization, and a strategic collaboration with Apollo Hospitals for AI algorithm development.

Differentiator

Problem solved

Functional benefit

Brands

• VisionAI Platform: AI-powered platform for early disease detection including diabetic retinopathy, cardiovascular risk assessment, type 2 diabetes risk, liver fibrosis detection, and chronic kidney disease progression.
• AICVD Cardiac Risk Score
• Prediabetes AI Risk Assessment
• AI Liver Fibrosis Risk Score
• CKD Progression Risk Model

Products and services

• VisionAI Platform

Quantifiable outcome

• Over 90% diagnostic accuracy for diabetic retinopathy detection
• +5 more outcomes

Named customers5 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature8 records

Partnerships

Nine partnerships are on record, tiered core, flagship and minor.

• InnerScope Hearing TechnologiescoreStrategic or Co-development Partner · 22 October 2025Strategic alliance in Ainnova Tech's pending acquisition of OTCHealth Inc. InnerScope is leveraging its retail agreements and technology pipeline to expand reach and foster innovation in hearing health and preventive healthcare. Transaction involves transfer of retail operations including agreements with major U.S. pharmacy chains to OTCHealth, now a subsidiary of Ainnova.
• OTCHealth Inc.coreOthers · 22 October 2025Pending acquisition target. Retail operations including agreements with major U.S. pharmacy chains being transferred to OTCHealth, now a subsidiary of Ainnova Tech. Enables national retail reach for hearing health and preventive healthcare products.
• Apollo HospitalscoreTechnology or Integration · 10 March 2025Strategic collaboration with Apollo Hospitals securing exclusive license for AI algorithms validated with over 2.3 million data points. Commercial pilot programs launching across the Americas with expansion planned for Brazil pending ANVISA regulatory approval. Deployment for early detection of cardiovascular disease, chronic kidney disease, liver fibrosis, type 2 diabetes, and lung abnormalities.
• Avant TechnologiesflagshipStrategic or Co-development Partner · 12 November 2024Formed joint venture through Ai-nova Acquisition Corp to commercialize Ainnova's VisionAI platform and retinal camera technology for early disease detection across North America and Europe. Partnership leverages Avant's capital investment to scale AI-powered diagnostic solutions including diabetic retinopathy screening and cardiovascular risk assessment through opticians and eye care centers. Avant is pursuing full acquisition of Ainnova Tech.
• Zappy Zapolin (Board Advisor)minorOthers · 30 August 2024Renowned entrepreneur and visionary joins Ainnova's Board of Advisors bringing decades of experience in strategic leadership, innovation, and brand development.
• Ian K. Gordon (Board Advisor)minorOthers · 30 July 2024Over 30 years of diverse experience in U.S. healthcare system with key roles in operations, technology, and strategy at major healthcare organizations. Joins Board of Advisors.
• ITEKminorStrategic or Co-development Partner · 1 June 2024Collaboration to create AI-powered affordable imaging device for early disease detection. Highlights commitment to revolutionizing retinal image capture and providing accessible solutions for early-stage disease detection.
• Marcus Dantus (Board Advisor)minorOthers · 6 October 2022Shark of TV Show Shark Tank Mexico joins as board advisor to drive growth and global expansion strategy.
• Manuel Zuñiga (Board Member) and Chad Harman (Board Director)minorOthers · 23 March 2022Manuel Zuñiga appointed as board member and Chad Harman as board director to fortify leadership team.

Scale indicators13 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Eyenuk: Direct competitor offering EyeArt, an FDA-cleared AI system for autonomous detection of diabetic retinopathy from retinal fundus images. Closest comparable on core product, target customer (primary care, optometry, retail optical), and regulatory pathway.
• Digital Diagnostics (IDx): Pioneer of IDx-DR, the first FDA-authorized autonomous AI diagnostic system for diabetic retinopathy, now part of Topcon Healthcare. Directly competes with VisionAI in retail optical and primary care DR screening channels.
• AEYE Health: AEYE-DS is an FDA-cleared AI for diabetic retinopathy screening from a single retinal image, targeted at primary care and retail pharmacy settings. Highly comparable in product scope, deployment model, and customer segments.
• RetinaLyze: European-based AI vendor for retinal image analysis (DR, AMD, glaucoma), offering screening tools to opticians and primary care. Comparable in applying AI to non-mydriatic retinal images for early disease detection.

Broad incumbents

• Topcon Healthcare: Acquired Digital Diagnostics (IDx) and is building a broad AI-driven eye-care platform across retinal imaging hardware, screening software, and integrated care pathways. Wider portfolio than Ainnova, but the AI screening module competes head-on with VisionAI.
• Optos: Manufacturer of ultra-widefield retinal imaging hardware (optomap), now part of Nikon Healthcare. Comparable as a retinal-imaging vendor whose installed base of cameras is a deployment surface for DR/disease-screening AI software like VisionAI.
• Carl Zeiss Meditec: Major ophthalmic device manufacturer with a broad portfolio of retinal imaging systems (OCT, fundus cameras) used by the same optometry/ophthalmology customers that Ainnova targets with VisionAI. Encompasses the imaging hardware ecosystem in which Ainnova's software sits.

Emerging players

• Nanox (formerly Zebra Medical Vision): AI imaging diagnostics company with multi-disease AI algorithms on radiology (and historically CT/mammography) imaging; comparable as a multi-condition AI diagnostics platform with regulatory ambition, but anchored in radiology rather than retinal imaging.
• Tempus Labs: AI-driven precision medicine company applying machine learning to clinical and molecular data for disease risk and treatment prediction. Comparable as an AI platform that derives multiple disease-risk models (cardiovascular, oncology) from clinical inputs, mirroring VisionAI's multi-condition approach.

Others

• HeartFlow: Commercial-stage AI diagnostics company that derives cardiovascular disease risk from imaging data (CT angiography). Comparable as a peer in AI-driven cardiovascular risk assessment — directly relevant to Ainnova's AICVD Cardiac Risk Score module.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ainnova Tech